Ensoma

Ensoma

Edit info

  • Founded: 2019
  • Location: Boston, MA
  • Employee range: 50 - 200
  • Clinical stage: RD
  • Therapy area: Oncology
  • Drug types: RD
  • Lead product: Undisclosed
  • Funding: $50M B May 2023; $85M B Jan 2023; $71M A Feb 2021
  • Investors: Kite, Bioluminescence Ventures, Delos Capital, SymBiosis


ensoma.com

linkedin.com

job board


About:

Ensoma is developing in vivo treatments for immuno-oncology. With their name derived from the Greek phrase “en soma”, meaning in the body, Ensoma’s approach is built on the view that the future of medicine lies within us. To develop therapies, Ensoma is using their EngeniousTM platform that combines delivery technology with the full DNA editing toolkit within a single platform. Ensoma is targeting the hematopoietic system since it is the source of blood and immune cells for the body and is linked with health and disease. Through in vivo editing of the immune system, Ensoma can engineer the body’s natural defenses to overcome the immuno-suppressive abilities of tumors and can engineer multiple cell types simultaneously offering an innovative way to treat cancer.

Jobs:

Ensoma
Analytical Scientist, Analytical Development
Boston, MA|7 days ago
Apply
Ensoma
Associate Director, Gene Editing (Protein Design)
Boston, MA|20 days ago


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com